Skip to main content
Premium Trial:

Request an Annual Quote

Microarrays Inc. Expands into European Market with Three Distribution Deals

Premium

By Justin Petrone

Microarrays Inc. last week announced distribution agreements with several companies, expanding its commercial activities for the first time into various European markets.

The Huntsville, Ala.-based firm has tapped Cambio to distribute its products in the UK and Ireland; BioCat to cover Germany, Austria, and Switzerland; and Biosolutions to sell its arrays to customers in Cyprus, Greece, and other Balkan countries.

The trio of firms will serve as exclusive distributors for MI products and services, including MI's custom arrays for the biological research, detection, and diagnostics markets, the company said.

Andrew Jennings, the firm's president of business development, said in a statement that MI is counting on its partners' "knowledge of the local biotechnology landscape" to "drive its growth in Europe."

Founded in 1999, MI has its origins in the Microarray Core facility of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville, Tenn. The firm was established as an autonomous company in November 2000 and relocated to the HudsonAlpha Institute for Biotechnology in Huntsville eight years later. MI has been privately held since May 2010 (BAN 7/20/2010).

The firm offers catalog and custom DNA, protein, antibody, and small-molecule arrays. It also offers array assay development services.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more